While vaccination programmes continue to scale up around the world, therapeutics play a key role in saving lives, freeing up capacity in intensive care units and treating patients living with long-COVID. 

The pharmaceutical industry is working around the clock to develop new tools to help patients and clinicians fight COVID-19. There are currently nearly 3000 clinical trials exploring therapeutics for treating COVID patients and around 61 therapeutic candidates such as anti-virals, monoclonal antibodies, anti-hypertensives, anti-inflammatories, immunomodulators, anti-thrombotics and steroids in the latter stages of development. 

The European Commission's COVID-19 Therapeutics Strategy aims to accelerate the continued development, delivery and availability of therapeutics for use in the fight against COVID-19 in Europe and around the world. 

• Jenny Camaradou, EUPATI Fellow Patient Expert, Innovation R&D consultant and COVID-END Horizon scanning Global Panel Member
• Pierre Delsaux, Deputy Director General, DG for Health and Food Safety, European Commission
• Massimiliano Di Domenico, VP Communications, Government Affairs and Market Access Europe, GlaxoSmithKline (GSK)
• Michel Goldman, President of the Institute for Interdisciplinary Innovation in healthcare (Université Libre de Bruxelles, Belgium) and former IMI Executive Director
• Nathalie Moll, Director General of EFPIA